Premium
Validation of the mantle cell lymphoma international prognostic index: A single‐center retrospective analysis
Author(s) -
Smith Stephen D.,
Hsi Eric,
Bolwell Brian,
Pohlman Brad,
Dean Robert,
Effinger Meagan,
Maggiotto Amanda,
Sweetenham John
Publication year - 2010
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21705
Subject(s) - mantle cell lymphoma , single center , international prognostic index , medicine , retrospective cohort study , index (typography) , oncology , center (category theory) , lymphoma , diffuse large b cell lymphoma , computer science , chemistry , world wide web , crystallography
Mantle cell lymphoma (MCL) is a unique, recently recognized entity with a variable clinical course [1]. Its historical grouping as an indolent lymphoma belies its common behavior, which is generally aggressive and incurable, with a median survival of about 5 years with modern therapy [2]. In an effort to improve outcomes in MCL, intensified therapies, including the rituximab plus HyperCVAD regimen [3] and incorporation of hematopoetic progenitor cell transplantation (HPCT) [4-6], have been used. However, although capable of inducing remissions in most patients, there is little proof that intensive first-line therapy prolongs overall survival (OS), and a continual relapse pattern is commonly observed [4,7-10].